New automated analytical platforms based on FISH technologies and tissue microarray methods are providing a rapid means to determine the impact of consistent genomic aberrations in clinical trials, and in studies designed to investigate differential chemotherapeutic response.
Expanded microarray methods are provided in the Detailed Materials and Methods (Appendix S1).
Microarray methods were modified from [ 92].
Commercial DNA microarray methods are marketed and increase the convenience of those tests [ 97].
ERα status associated genes identified in previous breast cancer studies [ 12, 13] using DNA microarray methods were compared with our SAGE findings.
In the study by Bermúdez et al. [ 14], microarray methods were used to examine the expression of linearly amplified RNA from individual oocytes and groups of five oocytes.
The NM-CGH microarray method is currently available for mutation analysis in our laboratory.
The DNA microarray method is found to be more sensitive in comparison to labor-intensive semiquantitative RT-PCR method, which gives data for a few gene transcripts.
Thus, the microarray method is a device with high specificity and less sensitivity, compared to the Taqman assay.
The protein microarray method is currently being established as a powerful tool for detecting proteins, observing their expression levels, and probing their interactions and functions.
